These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 20936622)
1. Thalidomide derivatives for the treatment of neuroinflammation. Contino-Pépin C; Parat A; Patinote C; Roscoe WA; Karlik SJ; Pucci B ChemMedChem; 2010 Dec; 5(12):2057-64. PubMed ID: 20936622 [TBL] [Abstract][Full Text] [Related]
2. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Contino-Pépin C; Parat A; Périno S; Lenoir C; Vidal M; Galons H; Karlik S; Pucci B Bioorg Med Chem Lett; 2009 Feb; 19(3):878-81. PubMed ID: 19103485 [TBL] [Abstract][Full Text] [Related]
3. Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE). Corrêa JO; Aarestrup BJ; Aarestrup FM Exp Neurol; 2010 Nov; 226(1):15-23. PubMed ID: 20406639 [TBL] [Abstract][Full Text] [Related]
4. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803 [TBL] [Abstract][Full Text] [Related]
5. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Bolton C Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249 [TBL] [Abstract][Full Text] [Related]
7. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Palaszynski KM; Liu H; Loo KK; Voskuhl RR J Neuroimmunol; 2004 Apr; 149(1-2):84-9. PubMed ID: 15020068 [TBL] [Abstract][Full Text] [Related]
8. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Berard JL; Wolak K; Fournier S; David S Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195 [TBL] [Abstract][Full Text] [Related]
9. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
17. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Steinman L; Zamvil SS Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891 [TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. Li FQ; Sempowski GD; McKenna SE; Laskowitz DT; Colton CA; Vitek MP J Pharmacol Exp Ther; 2006 Sep; 318(3):956-65. PubMed ID: 16740622 [TBL] [Abstract][Full Text] [Related]
19. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342 [TBL] [Abstract][Full Text] [Related]
20. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption. Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]